Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease (ARTIST-CKD)

University Medical Center Groningen (UMCG)

Status and phase: Begins enrollment this month; Phase 2

Conditions: Chronic Kidney Disease

Treatments: Drug: Survodutide (BI 456906); Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07206290

2025-523184-37-00 (EU Trial (CTIS) Number)

22774

Details and patient eligibility

About

The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years
• eGFR ≥20 and <90 mL/min/1.73m2
• Urinary albumin to creatinine ratio >30 mg/g and <3500 mg/g
• BMI >21 kg/m2
• Stable kidney function (no more than 30% change in eGFR in the 3 months prior to enrolment)
• On a stable maximum tolerated dose of an ACEi/ARB for at least 4 weeks prior to enrolment
• If using an SGLT2 inhibitor, receiving a stable dose for at least 8 weeks prior to enrolment
• Willing to sign an informed consent

Exclusion criteria

• Diagnosis of type 1 diabetes

• Cardiovascular event within 3 months prior to enrolment

• Treatment with GLP-1RA for <12 weeks prior to screening

• Evidence of severe hepatic impairment determined by any one of: ALT or AST values exceeding 3x ULN, a history of hepatic encephalopathy, a history of oesophageal varices, or a history of portocaval shunt;

• Active pregnancy or breastfeeding

• History of kidney or liver transplant

• Active malignancy

• Suggestive evidence of adrenal insufficiency

• Acute pancreatitis <180 days prior to screening

• History of chronic pancreatitis or idiopathic acute pancreatitisPersonal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma

• Calcitonin levels ≥100 pg/mL or 29.26 pmol/L

• Personal history of non-familial medullary thyroid carcinoma

• History of severe hypersensitivity or contraindications to any glucagon RA or GLP-1 RA

• Uncontrolled arterial hypertension (mean semi supine systolic blood pressure (SBP) ≥180 mmHg or diastolic blood pressure (DBP) ≥110 mmHg)

• Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:

  • History of active inflammatory bowel disease within the 6 months;
  • Major gastrointestinal tract surgery as determined by the physician;
  • Pancreatitis within 6 months.
  • GI ulcers and/or bleeding within 6 months;
  • Evidence of urinary obstruction or difficulty in voiding at screening.

• Participation in any clinical trial within 3 months prior to initial dosing.

• Donation or loss of ≧400 ml blood within 8 weeks prior to initial dosing.

• History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening or according to investigator's assessment.

• History of noncompliance to medical regimens or unwillingness to comply with the study protocol.

• Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.

• Women of childbearing potential (WOCBP):

  • WOCBP who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of study drug in such a manner the risk of pregnancy is minimized.
  • WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent of HCG) at screening.

• Vulnerable (i.e. under guardianship) or mentally incapacitated subjects (i.e. not able to understand and sign the informed consent)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

120 participants in 2 patient groups, including a placebo group

Survodutide

Experimental group

Description:

2:1 fashion to a 16 weeks up-titration phase of survodutide (0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg and 3.6 mg subcutaneous injection weekly) followed by a 20 weeks maintenance phase of survodutide s.c. 3.6 mg once weekly

Treatment:

Drug: Survodutide (BI 456906)

Placebo

Placebo Comparator group

Description:

Matching Placebo

Treatment:

Drug: Placebo